Literature DB >> 15897016

High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study.

Yoshihiko Shimokawa1, Hitoshi Akiyama, Eiji Kashiyama, Toshihisa Koga, Gohachiro Miyamoto.   

Abstract

High performance liquid chromatographic (HPLC) methods were validated for the determination of aripiprazole (OPC-14597, Abilify) in rat plasma and brain. Separation was by Nova-pak phenyl column; flow rate, 1.0 ml/min; mobile phase, acetonitrile-methanol-20 mM sodium sulfate-acetic acid (27:25:48:1, v/v/v/v); UV detection at 254 nm. Reproducibility in plasma and brain showed excellent precision (within 7.8 and 10.6%) and accuracy (96.0-102.4% and 99.0-108.7%) with calibration curve ranges 10.0-2000 ng/ml and 30.0-6000 ng/g, respectively. Validated HPLC methods were successfully applied to pharmacokinetic study of aripiprazole in rats, demonstrating brain concentrations after oral administration five times higher than plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897016     DOI: 10.1016/j.jchromb.2005.03.024

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  15 in total

1.  Validated spectrophotometric quantification of aripiprazole in pharmaceutical formulations by using multivariate technique.

Authors:  Kandikonda Sandeep; Madhusudhanareddy Induri; Muvvala Sudhakar
Journal:  Adv Pharm Bull       Date:  2013-08-20

2.  State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia.

Authors:  Susan F Sonnenschein; Kathryn M Gill; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2018-09-18       Impact factor: 7.853

3.  Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.

Authors:  Mirjana Carli; Eleonora Calcagno; Pierangela Mainolfi; Ester Mainini; Roberto W Invernizzi
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

4.  Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.

Authors:  Fausto A Varela; Taleen Der-Ghazarian; Ryan J Lee; Sergios Charntikov; Cynthia A Crawford; Sanders A McDougall
Journal:  J Psychopharmacol       Date:  2013-09-17       Impact factor: 4.153

5.  Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse.

Authors:  Matthew W Feltenstein; Phong H Do; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2009-09-25       Impact factor: 4.530

6.  Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.

Authors:  Taku Nagai; Rina Murai; Kanae Matsui; Hiroyuki Kamei; Yukihiro Noda; Hiroshi Furukawa; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2008-08-06       Impact factor: 4.530

7.  Effects of dopamine D2/D3 receptor ligands on food-cocaine choice in socially housed male cynomolgus monkeys.

Authors:  Paul W Czoty; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2012-12-04       Impact factor: 4.030

8.  Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats.

Authors:  Morgane Thomsen; Anders Fink-Jensen; David P D Woldbye; Gitta Wörtwein; Thomas N Sager; Rene Holm; Lauren M Pepe; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2008-07-09       Impact factor: 4.530

9.  Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats.

Authors:  Barbara Bricker; Tanise Jackson; Bernard Boateng; Xue Y Zhu; Seth Y Ablordeppey
Journal:  Pharmacol Biochem Behav       Date:  2012-05-12       Impact factor: 3.533

10.  Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy.

Authors:  Barbara A Bricker; Kwame Peprah; Hye J Kang; S Y Ablordeppey
Journal:  Pharmacol Biochem Behav       Date:  2019-02-12       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.